Provided by Tiger Trade Technology Pte. Ltd.

Crescent Biopharma Inc

17.15
+0.92005.67%
Post-market: 17.150.00000.00%19:30 EDT
Volume:218.39K
Turnover:3.65M
Market Cap:637.02M
PE:-2.31
High:17.19
Open:16.39
Low:16.03
Close:16.23
52wk High:27.41
52wk Low:8.72
Shares:37.14M
Float Shares:15.95M
Volume Ratio:1.33
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.4105
EPS(LYR):-12.8150
ROE:-160.75%
ROA:-69.15%
PB:8.78
PE(LYR):-1.34

Loading ...

Crescent Biopharma grants inducement options for 35,325 shares; exercise price set at $13.50

Reuters
·
Mar 28

Crescent Biopharma Inc - Files for Prospectus of Resale of up to 19.6 Mln Ordinary Shares Offered by Selling Securityholders - SEC Filing

THOMSON REUTERS
·
Mar 18

Crescent Biopharma Grants Inducement Stock Options Under 2025 Incentive Plan

Reuters
·
Mar 07

Crescent Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Guggenheim Remains a Buy on Crescent Biopharma (CBIO)

TIPRANKS
·
Feb 27

Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate

Benzinga Earnings
·
Feb 26

Crescent Biopharma Inc Qtrly Net Loss $4.01

THOMSON REUTERS
·
Feb 26

Crescent Biopharma Inc: Revenue for Three and Twelve Months Ended December 31, 2025 Was $10.8 Mln

THOMSON REUTERS
·
Feb 26

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Feb 26

Crescent Biopharma Inc: Revenue Recognized in 2025 Is Result of $20 Mln Upfront Payment From Kelun-Biotech Pursuant to License Agreement for Cr-001

THOMSON REUTERS
·
Feb 26

Crescent Biopharma FY 2025 net loss widens to USD 153.9 million

Reuters
·
Feb 26

Crescent Biopharma Grants 24,600-Share Inducement Stock Options to New Hires

Reuters
·
Feb 19

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Fresh Del Monte Produce, Crescent Biopharma

Reuters
·
Feb 19

BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts

Reuters
·
Feb 19

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

TIPRANKS
·
Feb 18

Crescent Biopharma Doses First Patient in ASCEND Phase 1/2 Trial of CR-001 for Advanced Solid Tumors

Reuters
·
Feb 18

Crescent Biopharma Inc: Ascend Is First of Four Clinical Trials Across Portfolio Expected to Initiate in 2026

THOMSON REUTERS
·
Feb 18

Crescent Biopharma Announces First Patient Dosed in Ascend Phase 1/2 Clinical Trial of Cr-001 for the Treatment of Advanced Solid Tumors

THOMSON REUTERS
·
Feb 18

Crescent Biopharma Inc: Anticipates Reporting Proof-of-Concept Data in Q1 of 2027

THOMSON REUTERS
·
Feb 18